Immune checkpoint inhibitors (ICIs; i.e. anti-PD1, anti-PDL1, and anti-CTLA4) have revolutionized the therapeutic landscape in oncology.1, 2, 3 In particular, these compounds have increased the survival in both the metastatic and adjuvant settings in several types of malignancies.1, 2, 3 In a subset of metastatic patients, the duration of the response is so long that a cure might be hypothesized, and a treatment discontinuation strategy could be proposed.4, 5, 6, 7, 8, 9 In light of the long-term efficacy, some patients could also plan to have a child. This evidence concerns the gene CTLA4 and cancer.